Invectys Therapeutics
Nathalie YARED is a research scientist at Invectys since April 2022, with a strong background in immunology developed during a Doctorat en Immunologie at ImmunoConcEpT UMR5164 from August 2017 to September 2021. Key responsibilities included developing and validating animal models, harvesting biological samples, conducting studies to understand immune pathways, and ensuring meticulous planning and documentation of experiments. Nathalie possesses solid bench-level experience in cellular and immunological assays and cell culture techniques. Educational qualifications include a Master in Microbiologie et Immunologie and a Bachelor in Health Biology, both from Université de Bordeaux, alongside a Baccalauréat Scientifique from Lycée Sainte Marie Grand Lebrun.
This person is not in any offices
Invectys Therapeutics
Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. It was founded in 2010 by Pierre Langlade Demoyen and Simon Wayne-Hobson and is based in Paris.Invectys develops a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients.This allows virtually all cancers to be targeted. Invectys focuses its efforts on two highly prevalent tumor antigens: the nearly-universal tumor antigen telomerase that is critical to uncontrolled cell growth, and the HLA-G immune checkpoint expressed in over 50% of cancers.